RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q2 2019
Top Holdings52 positions
Rocket Pharmaceuticals Inc | 16.6M | $248.8M | 13.3% | $17.46 | -14.07% | 2 qtrssince 2019-Q1 | Increased 62 |
Alnylam Pharmaceuticals Inc | 2.2M | $159.5M | 8.5% | $80.50 | -9.87% | 2 qtrssince 2019-Q1 | Increased 95 |
PTC Therapeutics Inc | 3.1M | $141.2M | 7.5% | $39.10 | +15.08% | 2 qtrssince 2019-Q1 | Increased 72 |
Dicerna Pharmaceuticals Inc | 6.2M | $96.9M | 5.2% | — | — | 2 qtrssince 2019-Q1 | Decreased 0 |
STOKE THERAPEUTICS INC | 3.4M | $92.6M | 4.9% | $29.17 | 0.00% | 1 qtr | New 83 |
Sarepta Therapeutics Inc | 604,236 | $91.8M | 4.9% | $133.61 | +13.72% | 2 qtrssince 2019-Q1 | Increased 84 |
MILESTONE PHARMACEUTICALS IN | 3.5M | $91M | 4.9% | $27.15 | 0.00% | 1 qtr | New 83 |
Adverum Biotechnologies Inc | 6.3M | $75.1M | 4.0% | — | — | — | Increased 55 |
Bristol-Myers Squibb Co | 1.6M | $70.8M | 3.8% | $36.65 | -4.02% | 2 qtrssince 2019-Q1 | Increased 56 |
AXONICS INC | 1.5M | $62.9M | 3.4% | — | — | 2 qtrssince 2019-Q1 | Increased 54 |
Masimo Corp | 372,258 | $55.4M | 3.0% | $138.53 | +7.43% | 2 qtrssince 2019-Q1 | Increased 52 |
Vericel Corp | 2.6M | $49.2M | 2.6% | $17.57 | +7.49% | 2 qtrssince 2019-Q1 | Increased 53 |
ESTABLISHMENT LABS HLDGS INC | 1.9M | $41.4M | 2.2% | $23.43 | -6.16% | 2 qtrssince 2019-Q1 | Increased 67 |
| 2.1M | $40.2M | 2.1% | — | — | 2 qtrssince 2019-Q1 | Increased 59 | |
ACHILLION PHARMACEUTICALS IN | 13.9M | $37.2M | 2.0% | — | — | 2 qtrssince 2019-Q1 | Increased 46 |
MYOKARDIA INC | 723,455 | $36.3M | 1.9% | — | — | 2 qtrssince 2019-Q1 | Increased 47 |
PROQR THRAPEUTICS N V | 3.7M | $33.9M | 1.8% | $13.87 | -34.39% | 2 qtrssince 2019-Q1 | Unchanged 0 |
TRANSLATE BIO INC | 2.4M | $30.8M | 1.6% | — | — | 2 qtrssince 2019-Q1 | Increased 70 |
Agenus Inc | 10.1M | $30.3M | 1.6% | — | — | — | Increased 46 |
Illumina Inc | 82,000 | $30.2M | 1.6% | $358.12 | 0.00% | 1 qtr | New 66 |
RTW INVESTMENTS, LP manages $1.9B across 52 positions as of Q2 2019. Top holdings: RCKT (13.3%), ALNY (8.5%), PTCT (7.5%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 3/5.0.
Active quarter - 8 new positions, 6 exits, 29 increased. Top move: ALNY (INCREASED, conviction 95). Portfolio: $1.9B across 52 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR